Immedica Pharma has acquired 1 company of its own, including 1 in the last 5 years.
Immedica Pharma’s largest acquisition to date was in 2024, when it acquired Marinus Pharmaceuticals for $151M. Immedica Pharma has acquired in 1 US state. The Company’s most targeted sectors include life science (100%).
Solnavägen 3H,
Stockholm,
113 29
Sweden,
+46 (0)8 533 39 500
www.immedica.com
| Date | Target |
Value
$mlns |
Transaction Type | Acquirer | Seller |
SRC
Link |
||
|---|---|---|---|---|---|---|---|---|
| 2024-12-30 |
Marinus · Life Science
Radnor, Pennsylvania · www.marinuspharma.com Marinus is a commercial-stage pharmaceutical company dedicated to the development of innovative therapeutics for seizure disorders. The Company’s product, ZTALMY (ganaxolone) oral suspension CV, is an FDA-approved prescription medication introduced in the U.S. in 2022. Marinus is based in Radnor, Pennsylvania.
|
151
4.9x REVENUE |
Merger |
Immedica Pharma
|
- |
Unlimited Searches Unlimited Profile Views Build and Export Lists of
Mergr is a user-friendly database designed to simplify the complex world of private equity and M&A for busy professionals.
We created Mergr to eliminate the challenge of tracking company acquisitions, sales, and ownership, providing clear insights into investment firms and their activities. For example, explore an investment firm’s investment criteria, deal history, portfolio, and connections - organized to help you uncover opportunities and make informed decisions.
With Mergr, gain access to a comprehensive, interconnected web of transactions, investors, companies, and advisors - all in one place.
Full access to Mergr's investor, acquirer, and transaction data starts here.
